DBV Technologies S.A. (NASDAQ: DBVT)

DBV Technologies S.A., often recognized by its ticker symbol DBVT, operates within the biopharmaceutical industry. This clinical-stage company is dedicated to developing a unique technology platform, Viaskin, aimed at treating children suffering from food allergies through a novel method called epicutaneous immunotherapy (EPIT). EPIT involves delivering biologically active compounds to the immune system through intact skin, using Viaskin, an epicutaneous patch.

DBV Technologies' primary focus lies in the development and commercialization of its Viaskin product candidates. These products are designed to treat food allergies and other immunological conditions. The company's main products include Viaskin Peanut and Viaskin Milk, which are in various stages of clinical development for the treatment of peanut and cow's milk protein allergies, respectively.

Viaskin Peanut, the company's most advanced product candidate, has completed a global Phase 3 development program for the treatment of peanut allergic patients aged four to 11 years. This product is designed to desensitize patients to peanut protein, thereby reducing the risk of severe allergic reactions. Viaskin Milk, the second product candidate, is in development for the treatment of cow's milk protein allergy in children aged two to 17 years.

The company generates revenue through the development and commercialization of its Viaskin product candidates. Its primary sources of revenue come from grants and collaborations with pharmaceutical companies, as well as from the sale of its products to patients and healthcare providers.

DBV Technologies' strategy is to revolutionize the field of immunotherapy by creating safe, effective, and convenient therapies for patients with food allergies and other immunological conditions. Key elements of this strategy include continuing the development of Viaskin Peanut for toddlers and children with peanut allergy, seeking regulatory approval for Viaskin Peanut in the United States and the European Union, advancing the clinical development of additional Viaskin product candidates in major markets, and building a robust immunotherapy product pipeline using its innovative Viaskin technology platform.

DBV Technologies holds a competitive advantage in the field of epicutaneous immunotherapy due to its proprietary Viaskin technology platform. This platform has been designed to deliver biologically active compounds to the immune system through intact skin, making it a promising solution for a range of food allergies and other immunological conditions.

The company's Viaskin technology platform has demonstrated safety and efficacy in clinical trials, and it has the potential to treat various food allergies and immunological conditions. DBV Technologies is committed to developing safe, effective, and convenient therapies for patients with these conditions.